Cargando…

Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium

Age-related macular degeneration (AMD) is a common disease with a multifactorial aetiology, still lacking effective and curative therapies. Among the early events triggering AMD is the deterioration of the retinal pigment epithelium (RPE), whose fundamental functions assure good health of the retina...

Descripción completa

Detalles Bibliográficos
Autores principales: Catanzaro, Michele, Lanni, Cristina, Basagni, Filippo, Rosini, Michela, Govoni, Stefano, Amadio, Marialaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291861/
https://www.ncbi.nlm.nih.gov/pubmed/32581803
http://dx.doi.org/10.3389/fphar.2020.00844
_version_ 1783545984834338816
author Catanzaro, Michele
Lanni, Cristina
Basagni, Filippo
Rosini, Michela
Govoni, Stefano
Amadio, Marialaura
author_facet Catanzaro, Michele
Lanni, Cristina
Basagni, Filippo
Rosini, Michela
Govoni, Stefano
Amadio, Marialaura
author_sort Catanzaro, Michele
collection PubMed
description Age-related macular degeneration (AMD) is a common disease with a multifactorial aetiology, still lacking effective and curative therapies. Among the early events triggering AMD is the deterioration of the retinal pigment epithelium (RPE), whose fundamental functions assure good health of the retina. RPE is physiologically exposed to high levels of oxidative stress during its lifespan; thus, the integrity and well-functioning of its antioxidant systems are crucial to maintain RPE homeostasis. Among these defensive systems, the Nrf2-pathway plays a primary role. Literature evidence suggests that, in aged and especially in AMD RPE, there is an imbalance between the increased pro-oxidant stress, and the impaired endogenous detoxifying systems, finally reverberating on RPE functions and survival. In this in vitro study on wild type (WT) and Nrf2-silenced (siNrf2) ARPE-19 cells exposed to various AMD-related noxae (H(2)O(2), 4-HNE, MG132 + Bafilomycin), we show that the Nrf2-pathway activation is a physiological protective stress response, leading downstream to an up-regulation of the Nrf2-targets HO1 and p62, and that a Nrf2 impairment predisposes the cells to a higher vulnerability to stress. In search of new pharmacologically active compounds potentially useful for AMD, four nature-inspired hybrids (NIH) were individually characterized as Nrf2 activators, and their pharmacological activity was investigated in ARPE-19 cells. The Nrf2 activator dimethyl-fumarate (DMF; 10 μM) was used as a positive control. Three out of the four tested NIH (5 μM) display both direct and indirect antioxidant properties, in addition to cytoprotective effects in ARPE-19 cells under pro-oxidant stimuli. The observed pro-survival effects require the presence of Nrf2, with the exception of the lead compound NIH1, able to exert a still significant, albeit lower, protection even in siNrf2 cells, supporting the concept of the existence of both Nrf2-dependent and independent pathways mediating pro-survival effects. In conclusion, by using some pharmacological tools as well as a reference compound, we dissected the role of the Nrf2-pathway in ARPE-19 stress response, suggesting that the Nrf2 induction represents an efficient defensive strategy to prevent the stress-induced damage.
format Online
Article
Text
id pubmed-7291861
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72918612020-06-23 Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium Catanzaro, Michele Lanni, Cristina Basagni, Filippo Rosini, Michela Govoni, Stefano Amadio, Marialaura Front Pharmacol Pharmacology Age-related macular degeneration (AMD) is a common disease with a multifactorial aetiology, still lacking effective and curative therapies. Among the early events triggering AMD is the deterioration of the retinal pigment epithelium (RPE), whose fundamental functions assure good health of the retina. RPE is physiologically exposed to high levels of oxidative stress during its lifespan; thus, the integrity and well-functioning of its antioxidant systems are crucial to maintain RPE homeostasis. Among these defensive systems, the Nrf2-pathway plays a primary role. Literature evidence suggests that, in aged and especially in AMD RPE, there is an imbalance between the increased pro-oxidant stress, and the impaired endogenous detoxifying systems, finally reverberating on RPE functions and survival. In this in vitro study on wild type (WT) and Nrf2-silenced (siNrf2) ARPE-19 cells exposed to various AMD-related noxae (H(2)O(2), 4-HNE, MG132 + Bafilomycin), we show that the Nrf2-pathway activation is a physiological protective stress response, leading downstream to an up-regulation of the Nrf2-targets HO1 and p62, and that a Nrf2 impairment predisposes the cells to a higher vulnerability to stress. In search of new pharmacologically active compounds potentially useful for AMD, four nature-inspired hybrids (NIH) were individually characterized as Nrf2 activators, and their pharmacological activity was investigated in ARPE-19 cells. The Nrf2 activator dimethyl-fumarate (DMF; 10 μM) was used as a positive control. Three out of the four tested NIH (5 μM) display both direct and indirect antioxidant properties, in addition to cytoprotective effects in ARPE-19 cells under pro-oxidant stimuli. The observed pro-survival effects require the presence of Nrf2, with the exception of the lead compound NIH1, able to exert a still significant, albeit lower, protection even in siNrf2 cells, supporting the concept of the existence of both Nrf2-dependent and independent pathways mediating pro-survival effects. In conclusion, by using some pharmacological tools as well as a reference compound, we dissected the role of the Nrf2-pathway in ARPE-19 stress response, suggesting that the Nrf2 induction represents an efficient defensive strategy to prevent the stress-induced damage. Frontiers Media S.A. 2020-06-05 /pmc/articles/PMC7291861/ /pubmed/32581803 http://dx.doi.org/10.3389/fphar.2020.00844 Text en Copyright © 2020 Catanzaro, Lanni, Basagni, Rosini, Govoni and Amadio http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Catanzaro, Michele
Lanni, Cristina
Basagni, Filippo
Rosini, Michela
Govoni, Stefano
Amadio, Marialaura
Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium
title Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium
title_full Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium
title_fullStr Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium
title_full_unstemmed Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium
title_short Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium
title_sort eye-light on age-related macular degeneration: targeting nrf2-pathway as a novel therapeutic strategy for retinal pigment epithelium
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291861/
https://www.ncbi.nlm.nih.gov/pubmed/32581803
http://dx.doi.org/10.3389/fphar.2020.00844
work_keys_str_mv AT catanzaromichele eyelightonagerelatedmaculardegenerationtargetingnrf2pathwayasanoveltherapeuticstrategyforretinalpigmentepithelium
AT lannicristina eyelightonagerelatedmaculardegenerationtargetingnrf2pathwayasanoveltherapeuticstrategyforretinalpigmentepithelium
AT basagnifilippo eyelightonagerelatedmaculardegenerationtargetingnrf2pathwayasanoveltherapeuticstrategyforretinalpigmentepithelium
AT rosinimichela eyelightonagerelatedmaculardegenerationtargetingnrf2pathwayasanoveltherapeuticstrategyforretinalpigmentepithelium
AT govonistefano eyelightonagerelatedmaculardegenerationtargetingnrf2pathwayasanoveltherapeuticstrategyforretinalpigmentepithelium
AT amadiomarialaura eyelightonagerelatedmaculardegenerationtargetingnrf2pathwayasanoveltherapeuticstrategyforretinalpigmentepithelium